Skip to main content Skip to navigation
Purified Mouse Anti-Human CD77
Product Details
Down Arrow Up Arrow

BD Pharmingen™
Human (QC Testing)
Mouse BALB/c IgM, κ
Initially Adherent Human Peripheral Blood Cells
Flow cytometry (Routinely Tested)
0.5 mg/ml
VI CD77.5
Aqueous buffered solution containing ≤0.09% sodium azide.

Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4°C.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
551352 Rev. 4
Antibody Details
Down Arrow Up Arrow

The 5B5 monoclonal antibody specifically binds to human CD77, a small neutral glycosphingolipid also referred to as globotriaosylceramide (Gb3), Burkitt 's lymphoma associated antigen (BLA), ceramide trihexoside (CTH), and Pk blood group antigen. CD77 is expressed on a subset of germinal center B-lymphocytes including centroblasts that are found with greater frequency in tonsil and mucosal lymphoid tissues and less frequently in peripheral blood, bone marrow and spleen. It has been described as a receptor for Shiga Toxin, produced by Shigella dysenteriae, and Verotoxin 1 (VT1), produced by some strains of E. coli. CD19 has been reported as a ligand for CD77. This interaction may function in adhesion and signal transduction at a specific stage of B cell differentiation. Studies have shown that cross-linking CD77 induces apoptosis in some B cell lines.

This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

551352 Rev. 4
Format Details
Down Arrow Up Arrow
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
551352 Rev.4
Citations & References
Down Arrow Up Arrow
View product citations for antibody "551352" on CiteAb

Development References (4)

  1. Fyfe G, Cebra-Thomas JA, Mustain E, Davie JM, Alley CD, Nahm MH. Subpopulations of B lymphocytes in germinal centers. J Immunol. 1987; 139(7):2187-2194. (Biology). View Reference
  2. Lagresle C, Bella C, Daniel PT, Krammer PH, Defrance T. Regulation of germinal center B cell differentiation. Role of the human APO-1/Fas (CD95) molecule. J Immunol. 1995; 154(11):5746-5756. (Biology). View Reference
  3. Maloney MD, Lingwood CA. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med. 1994; 180(1):191-201. (Biology). View Reference
  4. Mangeney M, Rousselet G, Taga S, Tursz T, Wiels J. The fate of human CD77+ germinal center B lymphocytes after rescue from apoptosis. Mol Immunol. 1995; 32(5):333-339. (Biology). View Reference
View All (4) View Less
551352 Rev. 4

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.